Clinical Trials Browser

Phase 2/3 × INDUSTRY × lenvatinib × Clear all

NCT05033522 2025-10-23

ALIVE

Phase 2/3 Suspended

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05001724 2023-04-25

KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent

Phase 2/3 Terminated

Advanced Non-small Cell Lung Cancer